awmsg logo



lacosamide (Vimpat®)


Reference No. 1295

Publication date:
03/04/2017


Appraisal information

lacosamide (Vimpat®) multiple formulations


Company: UCB Pharma Ltd
BNF category: Central nervous system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 03/04/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, lacosamide (Vimpat®) cannot be endorsed for use within NHS Wales as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
Statement of Advice (SOA)
Download